DEVELOPMENT AND PHYSICO-CHEMICAL EVALUATION OF MONOLITHIC MATRIX TYPE TRANSDERMAL FILMS OF AMMONIA METHACRYLATE COPOLYMER-METHOCEL AND METHACRYLIC ACID COPOLYMER-METHOCEL OF A MODEL ANTI-HYPERTENSIVE DRUG by Bhowmick, Mithun et al.
Bhowmick et al                                  Journal of Drug Delivery & Therapeutics; 2014, 4(1), 5-14    5 
© 2011, JDDT. All Rights Reserved                                                  ISSN: 2250-1177                                                    CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
RESEARCH ARTICLE 
DEVELOPMENT AND PHYSICO-CHEMICAL EVALUATION OF MONOLITHIC 
MATRIX TYPE TRANSDERMAL FILMS OF AMMONIA 
METHACRYLATE COPOLYMER-METHOCEL AND METHACRYLIC ACID 
COPOLYMER-METHOCEL OF A MODEL ANTI-HYPERTENSIVE DRUG 
Mithun Bhowmick*, Dr. Tamizharasi Sengodan, Dr. Sivakumar Thangavel 
Dept. of Pharmaceutics, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India 
*Corresponding Author’s E-mail:    bhowmick_theyoungscientist@ymail.com, Contact No.:- +91-9754931377 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
It was planned to design the formulation in such a way 
that it provides the delivery of drug at a controlled rate 
across intact human skin to achieve a therapeutic 
effective drug level for a longer period of time. The 
polymeric monolithic matrix type transdermal films are 
widely used to provide controlled delivery of drug 
substances because of their versatility, effectiveness, and 
low cost. These types of systems are also suitable for in-
house development because they are usually 
manufactured using conventional equipment and 
processing. The benefits of using transdermal drug 
delivery include improved systemic bioavailability 
resulting from bypassing the first hepatic metabolism. 
Variables due to oral administration, such as pH, the 
presence of food or enzymes, and transit times can all be 
eliminated.  The aim in the development of new 
transdermal drug delivery device is to obtain a 
controlled, predictable, and reproducible release of the 
drug into the blood stream of the patient.1,2 
The first and most important parameter for the 
development of a polymeric film is the choice of 
polymer. Besides having good film-forming properties 
and being a non-skin-irritant, the polymer must be 
soluble in a skin-tolerant solvent. The investigated 
polymers comprised combination of polymers - 
Ammonio Methacrylate Copolymers such as Eudragit 
RLPO (ERLPO) and Eudragit RSPO (ERSPO) with 
hydrophilic polymer Methocel K15M (MK15M) and 
combination of polymers such as Methacrylic acid co-
polymers Acrylcoat L100 (AL100) and Acrylcoat S100 
(AS100) with hydrophilic polymer MK15M. A great 
effort has been devoted to optimize the innovated films 
as far as possible. However, optimal properties cannot be 
achieved for a single polymer. Therefore, blending of 
polymers is necessary to attain more suitable transdermal 
devices regarding properties and performance. These 
transdermal delivery systems are neither extremely 
hydrophobic nor extremely hydrophilic. Binary blends of 
MK15M and the different types of Ammonio 
Methacrylate Copolymers & Methacrylic acid co-
polymers in different concentration were done to 
ameliorate physicochemical properties and to optimize 
performance. Beside the other components of 
transdermal patches, plasticizers also significantly 
change the viscoelastic properties of the polymers by the 
improvement of film forming properties and the 
appearance of the film, preventing film cracking, 
increasing film flexibility and obtaining desirable 
mechanical properties. The plasticizers tried in 
optimization trials were lipophilic plasticizers Dibutyl 
Phathalate (DBP) & Dibutyl Sebacate (DBS) and 
hydrophilic plasticizers Polyethylene glycol 400 (PEG 
400) & Propylene Glycol (PG). In this research work, 2 
different permeation enhancers of Terpene class such as 
d- limonene and 1,8 cineole were used. They were used 
in combinations so that more effective and enhanced 
transdermal drug transport can be obtained by synergism 
and it’s also safe as the strength of individual enhancers 
can be reduced without compromising on drug release. 
Drug of choice Monolithic matrix transdermal 
therapeutic systems is Metoprolol Tartrate. Metoprolol 
tartrate is prferred because of its relative β-1 selectivity, 
it is safe for use in patients with bronchospastic disease. 
Metoprolol tartrate has a oral bioavailability of only 38 
% due to extensive hepatic first-pass metabolism. The 
half-life of the Metoprolol is about 3.2 hours, which 
makes frequent dosing necessary to maintain the 
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therapeutic blood levels of the drug for long-term 
treatment.3-7 
MATERIAL AND METHODS 
Materials 
Metoprolol tartrate is obtained from Emcure 
Pharmaceuticals Pvt. Ltd., Pune. Eudragit RSPO and 
Eudragit RLPO are obtained from Evonik Degussa India 
pvt. Ltd.,Mumbai. Acrylcoat S100 and Acrylcoat L100 
are obtained from Corel Pharma chem., Ahmedabad 
,Methocel K15M is obtained from Colorcon Asia Pvt. 
Ltd, Goa. Plasticzers and permeation enhancers are 
obtained from Merck India Ltd. Mumbai and Himedia, 
Mumbai respectively. All other chemicals used are 
procured from S.D. Fine Chemicals, Mumbai 
Methods 
Dose Calculation for Monolithic Matrix type 
Transdermal films
8
 
The dose to be incorporated in a patch was calculated 
using the following mathematical equation- 
Drug input (theoretical) = Css *Ke * Vd 
Where Css is concentration at steady state, ke is 
elimination rate constant and Vd is volume of distribution 
Volume of distribution (Vd) = 290 L/ 70kg 
                                             =290000 ml 
Concentration at steady state (C ss)/target concentration  
   = 25 ng/ml 
= 25 ×10-6 mg/ml 
Half -life of MT (t1/2) = 3.2 hr 
Elimination rate constant (k e) = 0.693 ÷ t1/2    
                                                 = 0.693 ÷ 3.2 
                                                 = 0.21666 hr-1         
Drug input (theoretical) = Css *Ke * Vd 
                                                          = 25 ×10
-6×0.2166 ×290000 
                                       = 1.570 mg/hr 
Maintenance dose for 24 hours (for therapeutic activity)= 
1.570×24 =37.68 mg/24 hr 
Expected bioavailability of the drug from the TDDS 
patch (Expected drug that will reach the blood plasma 
after crossing the skin as a barrier) = 75% 
Amount of the drug to be incorporated in each 
transdermal patch = 37.68×100/75 
= 50.24 mg ≈ 50 mg 
Internal diameter of petriplate / glass mould = 9.2 cm 
Internal surface area of mould = πr2 = 22/7 x (4.6)2 
                                                     = 66.49 cm2 
Diameter of transdermal patch = 2 cm 
Area of transdermal patch = πr2 = 22/7 x (1)2 
                                                   = 3.14 cm2 
Amount of drug loaded per unit area= 50mg/3.14 cm2  
                                               = 15.92 mg/ square 
centimeter patch 
Number of transdermal patches from one circular cast 
film: 
=66.49/3.14 = 21.175 ≈ 21 patches 
Amount of MT to be present in each TDDS patch =50 
mg 
Amount of MT should be loaded in one circular cast film 
= 50 x21 = 1050 mg 
10 ml of the solution containing 1050 mg is poured in 
each mould of 66.49 cm2 area 
Fabrication of Drug loaded Monolithic Matrix type 
transdermal films: 
The Drug loaded Monolithic Matrix type transdermal 
films were prepared by film casting technique on 
mercury substrate using different ratios of 
ERLPO:MK15M, ERSPO:MK15M, AS100:MK15M 
and AL100:MK15M (1:4,2:3,3:2,4:1) containing drug 
MT (15.92 mg/ square centimeter patch).  The polymers 
were weighed in requisite ratios keeping the total 
polymer weight 500 mg constant. Hydrophilic materials 
i.e. MK15M was dissolved in water and hydrophobic 
material i.e. ERLPO or ERSPO or AS100 or AL100 was 
dissolved in blend of Methanol and Isopropyl alcohol 
(50:50). Then both the solution (MK15M solution was 
mixed separately with each hydrophobic polymer in 
different ratios) were mixed and stirred on magnetic 
stirrer to accomplished homogeneous mixture. The above 
polymeric dispersion was sonicated for 2 minutes to 
remove entrapped air bubbles.  In this study Lipophilic 
plasticizers DBP & DBS or hydrophilic plasticizers such 
as PEG 400 & PG was added for each polymer 
combination. Two different permeation enhancers of 
Terpene class such as limonene and cineole in different 
percentage in combination (2.5:2.5 w/w %) was added to 
each polymer combination. The resulting solution (10 
ml) was poured in a petri dish of 9.2 cm diameter 
containing mercury. The rate  of  evaporation  of  the  
solvent  was  controlled  by placing  an  inverted  funnel  
over  the  petri dish and allowed for drying over night 
followed by vacuum drying. The film formation  was  
noted  by  observing  the  mercury  surface after  
complete  evaporation  of  the  solvent. Aluminium foil 
was used as backing film and wax paper as release liner 
(which could be removed before application of the patch 
on the skin) were applied to complete the TDDS. The 
patches were cut with a circular metallic die of 2 cm 
internal diameter to give an area of 3.14 cm2 and stored 
in a desiccator until use. 1,2,9 
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Table 1: Composition of Drug loaded transdermal films EM1-EM8 
S.No. 
Formulation 
code 
Drug 
(mg/ square 
centimeter 
patch) 
Polymer combination 
with ratio 
Plasticizer 
type and 
Percentage 
(%w/w) 
Permeation Enhancer 
(%w/w) 
Limonene Cineole 
1.  EM1 15.92 ERSPO:MK15M (1:4) 
PEG 400 
(20%) 
2.5 2.5 
2.  EM2 15.92 
ERSPO: MK15M 
(2:3) 
PEG 400 
(20%) 
2.5 2.5 
3.  EM3 15.92 
ERSPO: MK15M 
(3:2) 
DBS (25%) 2.5 2.5 
4.  EM4 15.92 
ERSPO: MK15M 
(4:1) 
DBS (25%) 2.5 2.5 
5.  EM5 15.92 
ERLPO: MK15M 
(1:4) 
PEG 400 
(20%) 
2.5 2.5 
6.  EM6 15.92 
ERLPO: MK15M 
(2:3) 
PEG 400 
(20%) 
2.5 2.5 
7.  EM7 15.92 
ERLPO: MK15M 
(3:2) 
DBS (25%) 2.5 2.5 
8.  EM8 15.92 
ERLPO: MK15M 
(4:1) 
DBS (25%) 2.5 2.5 
 
Table 2: Composition of Drug loaded transdermal films AM1-AM8 
S.No. 
Formulation 
code 
Drug 
(mg/ square 
centimeter 
patch) 
Polymer combination 
with ratio 
Plasticizer 
type and 
Percentage 
(w/w %) 
Permeation Enhancer 
(%w/w) 
Limonene Cineole 
1.  AM1 15.92 AS100: MK15M (1:4) PG (15%) 2.5 2.5 
2.  AM2 15.92 AS100: MK15M (2:3) PG (15%) 2.5 2.5 
3.  AM3 15.92 AS100: K15M (3:2) PG (15%) 2.5 2.5 
4.  AM4 15.92 AS100: MK15M (4:1) DBT (30%) 2.5 2.5 
5.  AM5 15.92 AL100: MK15M (1:4) PG (15%) 2.5 2.5 
6.  AM6 15.92 AL100: MK15M (2:3) PG (15%) 2.5 2.5 
7.  AM7 15.92 AL100: MK15M (3:2) PG (15%)  2.5 2.5 
8.  AM8 15.92 AL100: MK15M (4:1) DBT (30%) 2.5 2.5 
 
EVALUATION OF FORMULATIONS: 
Physico-chemical evaluation 
The Physico-chemical properties of patches are among 
the factors, which determine the suitability and 
acceptability of the prepared patches. The thickness, 
weight, drug content, tensile strength, % elongation, 
folding endurance, flatness % absorption and % loss, 
swelling and pH were determined for the prepared 
patches. Physicochemical evaluation and appropriate 
quality control are essential to ensure safety and 
adequate performance of designed formulae. 
Physical appearance of formed films 
All the prepared patches were visually inspected for 
color, clarity, flexibility and smoothness.10 
Uniformity of Thickness  
The thicknesses of the drug-loaded polymeric films were 
measured at three different points using a digital 
micrometer (Mitutoyo, Japan). The average and standard 
deviation of three readings were calculated for each 
batch of the drug-loaded films.11,12 
Uniformity of weight 
A specified area (1 cm2) of patch is to be cut in different 
parts of the patch and is to be dried at 60°c for 4hrs 
before testing and Weight variation is studied by 
individually weighing 03 randomly selected patches and 
calculating the average weight. The individual weight 
should not deviate significantly from the average 
weight.13,14 
Uniformity of Drug content 
An accurately weighed portion of patch was placed in 
100 ml of 7.4 phosphate buffer and then the solution was 
shaken continuously for 24 hrs in shaker incubator. Then 
the whole solution was sonicated for complete extraction 
of drug from the patch. After incubation and subsequent 
filtration, drug in solution was estimated against the 
reference solution consisting of placebo films (contains 
no drug) with UV spectrophotometry at 274 nm.15,16 
Surface pH 
Surface  pH  of  the  patches  was  determined  by  the  m
ethod  described  by Bottenberg et al. 
The patches were allowed to swell by keeping them in co
ntact with 0.5 ml of double distilled     water for 1 hour i
n glass tubes. The surface pH was then noted by bringing
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 acombined glass electrode near the surface of the patch 
and allowing it to equilibrate for 1 minute.17 
Flatness 
A transdermal patch should possess a smooth surface and 
should not constrict with time. This can be demonstrated 
with flatness study. For flatness determination, one strip 
is cut from the centre and two from each side of patches. 
The length of each strip is measured and variation in 
length is measured by determining percent constriction.  
0% constriction is equivalent to 100 % flatness.18 
 
L2 = Final length of each strip 
L1 = Initial length of each strip 
Tensile Strength 
Tensile strength of the film was determined with 
Universal Strength Testing Machine. The sensitivity of 
the machine was 1 g. It consisted of two load cell grips. 
The lower one was fixed and upper one was movable. 
The test film of size (4×1cm2) was fixed between these 
cell grips and force was gradually applied till the film 
broke. Tensile strength is expressed as follows 19,20 
 
Percentage elongation break test  
The percentage elongation break is determined by noting 
the length just before the break point, the percentage 
elongation can be determined from the below mentioned 
formula 21 
 
Where, L1is the final length of each strip and L2 is the 
initial length of each strip. 
Folding endurance 
Evaluation of folding endurance involves determining 
the folding capacity of the films subjected to frequent 
extreme conditions of folding. Folding endurance is 
determined by repeatedly folding the film at the same 
place until it break; the number of times the films could 
be folded at the same place without breaking is folding 
endurance value.22 
Percentage moisture absorption 
Initial weight of the patch was taken and noted, then 
weighed patch are kept in desiccators at room 
temperature for 24 h. These are then taken out and 
exposed to 75% relative humidity using saturated 
solution of sodium chloride in desiccators until a 
constant weight is achieved. Final weight of the patch 
was calculated and percentage moisture uptake is 
calculated as given below.23 
 
Percentage moisture loss 
The prepared patch are weighed individually and kept in 
a desiccators containing fused calcium chloride at room 
temperature for 24 h. The patch is weighed again after a 
specified interval until they show a constant weight. The 
percent moisture content is calculated using following 
formula:24 
 
Swelling Studies  
Weight increase due to swelling was measured. The 
drug-loaded patch of size 1 x 1 cm2 was weighed on a 
pre-weighed cover slip. It was kept in a petridish and 50 
ml of phosphate buffer (pH 7.4) solution was added. 
After every five min, the cover slip was removed, wiped 
with tissue paper, and weighed upto 30 min. The 
difference in the weights gives the weight increase due to 
absorption of water and swelling of patch.25,26 
The percent swelling, %S was calculated using the 
following equation; 
 
Where Xt is the weight of the swollen patch after time t 
and Xo is the original patch weight at zero time. 
 
RESULT AND DISCUSSION 
Physico-chemical Evaluation of Formulations 
Physical appearance of formed films 
All the patches prepared with different polymer 
concentration were found to be flexible, translucent, hard 
and homogeneous in nature. 
Uniformity of Thickness  
Transdermal patches were transparent, smooth, 
uniform and flexible. The thickness of the weights 
ranged between 0.179±0.0051 to 0.258±0.0063 
formulations (EM1 to EM8 and AM1 to AM8). The 
result indicated that there was no much difference in the 
thickness within the formulations. Low standard 
deviation and % Relative standard deviation values in the 
film thickness measurements ensured uniformity of the 
films prepared by solvent evaporation method. If we 
compare among different polymer combination we found 
that as the proportion of Ammonio Methacrylate 
Copolymers or Methacrylic acid co-polymers was 
increased or as the proportion of MK15M was decreased, 
the thickness decreases. The uniformity of thickness of 
the formulation EM1-EM8 and AM1-AM8 were shown 
in table No.3 and table No.4 respectively.       
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Table 3 Uniformity of Thickness of formulations 
EM1-EM8 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation     
Table 4: Uniformity of Thickness of formulations 
AM1-AM8 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Uniformity of weight  
The weight of all the formulation varies between 
70.61±0.218-79.81±79.81±0.222 (EM1 to EM8 and 
AM1 to AM8). The result indicated that there was no 
much difference in the thickness within the formulations. 
Low standard deviation and % Relative standard 
deviation values in the weight of film measurements 
ensured uniformity of the films prepared by solvent 
evaporation method. we found that as the proportion of 
Ammonio Methacrylate Copolymers or Methacrylic acid 
co-polymers was increased or as the proportion of 
Methocel K15M was decreased, the weight decreases. 
Patches were favourable because these were thinner and 
less heavier and do not affect quality of life of patients 
and giving feel of bulkiness. The uniformity of weight of 
the formulation EM1-EM8 are shown in table No.5 and 
table No.6 respectively.  
Table 5 Uniformity of Weight of formulations EM1-
EM8 
Formulation 
code 
Weight (mg) 
Mean±SD 
 RSD % 
EM1 77.21±0.225 0.291 
EM2 75.03±0.221 0.294 
EM3 72.29±0.215 0.297 
EM4 70.61±0.218 0.308 
EM5 79.81±0.222 0.278 
EM6 77.24±0.211 0.273 
EM7 74.54±0.212 0.284 
EM8 72.37±0.215 0.297 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Table 6 Uniformity of Weight of formulations AM1-
AM8 
 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Uniformity of Drug content 
Homogeneous uniform drug distribution is one 
of the important characteristics of a transdermal patch 
that ensures the uniform reproducible sustained release 
of the drug from the patch. The drug content (%) of all 
the formulations was found to be more than 90%. The 
results of content uniformity indicated that the drug was 
uniformly dispersed. The results of content uniformity 
indicated that the drug was uniformly dispersed. 
Recovery was possible to the tune of 94.43±1.33 to 
95.77±0.83 for formulations EM1 to EM8 and 
94.20±1.25 to 96.33±±1.14 for formulations AM1 to 
AM8. The uniformity of drug content of the formulation 
EM1-EM8 are shown in table No.7 and table No.8 
respectively. 
Table 7: Uniformity of Drug content of formulations 
EM1-EM8 
 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
 
 
 
 
Formulation code 
Drug content(%) 
Mean±SD 
RSD % 
EM1 94.64±1.22 1.28 
EM2 95.13±1.31 1.37 
EM3 95.63±1.15 1.20 
EM4 94.71±1.05 1.11 
EM5 95.36±1.48 1.55 
EM6 95.77±0.83 0.86 
EM7 95.37±0.96 1.01 
EM8 94.43±1.33 1.41 
Formulation code 
Thickness(mm) 
Mean±SD 
RSD % 
EM1 0.225±0.0066 2.93 
EM2 0.214±0.0057 2.66 
EM3 0.188±0.0049 2.61 
EM4 0.179±0.0051 2.85 
EM5 0.258±0.0063 2.44 
EM6 0.244±0.0054 2.21 
EM7 0.225±0.0067 2.98 
EM8 0.214±0.0058 2.71 
Formulation code 
Thickness(mm) 
Mean±SD 
RSD % 
AM1 0.234±0.0052 2.22 
AM2 0.223±0.0063 2.83 
AM3 0.216±0.0060 2.78 
AM4 0.194±0.0057 2.93 
AM5 0.227±0.0059 2.59 
AM6 0.217±0.0053 2.44 
AM7 0.201±0.0051 2.53 
AM8 0.189±0.0055 2.91 
Formulation code 
Weight (mg) 
Mean±SD 
RSD % 
AM1 78.36±0.213 0.271 
AM2 75.56±0.219 0.289 
AM3 73.40±0.215 0.292 
AM4 71.50±0.222 0.310 
AM5 77.91±0.224 0.287 
AM6 75.37±0.212 0.281 
AM7 72.58±0.216 0.297 
AM8 70.66±0.218 0.308 
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Table 8: Uniformity of Drug content of formulations 
AM1-AM8 
Formulation code 
Drug content (%) 
Mean±SD 
RSD % 
AM1 95.36±1.16 1.22 
AM2 95.52±1.03 1.08 
AM3 94.20±1.25 1.32 
AM4 95.44±1.19 1.24 
AM5 95.23±1.28 1.34 
AM6 95.61±0.97 1.05 
AM7 96.33±1.14 1.19 
AM8 95.54±1.29 1.36 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Surface pH 
The surface pH of all the formulations was in th
e range of 5.2±0.154 to 5.90±0.145 (EM1 to EM8 and 
AM1 to AM8), these values are close to 
the pH range of skin (4.5-5.5)1 
and hence no skin irritation was expected. The 
surface pH of the formulations EM1-EM8 and AM1 to 
AM8) are shown in table No.8 and table No.9 
respectively. 
Table 8: Surface pH of formulations EM1-EM8 
Formulation code 
Surface pH 
 Mean±SD 
RSD % 
EM1 5.83±0.163 2.79 
EM2 5.35±0.158 2.95 
EM3 5.20±0.154 2.96 
EM4 5.66±0.159 2.80 
EM5 5.44±0.142 2.61 
EM6 5.31±0.122 2.29 
EM7 5.25±0.149 2.83 
EM8 5.75±0.121 2.10 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Table 9: Surface pH of formulations AM1-AM8 
Formulation 
code 
Surface pH  
Mean±SD 
RSD % 
AM1 5.85±0.169 2.88 
AM2 5.42±0.151 2.78 
AM3 5.55±0.161 2.91 
AM4 5.74±0.154 2.68 
AM5 5.32±0.159 2.98 
AM6 5.42±0.146 2.69 
AM7 5.90±0.145 2.45 
AM8 5.44±0.153 2.81 
SD: Standard deviation; n=3; RSD %: Percentage Relative 
Standard deviation 
Flatness (%) 
An idyllic patch should be formulated in such a way that 
it possesses a smooth surface and it should not constrict 
with time. Flatness studies were performed to judge the 
same. 
The %Flatness of all the formulations was in the range of
 99.12±1.01 to 99.68±1.11 (EM1 to EM8 and AM1 to 
AM8). The flatness study showed that all the 
formulations had the nearly same strip length before and 
after their cuts, indicating nearly 100% flatness, which 
indicates negligible amount of constriction of the 
prepared transdermal patches. The % Flatness of the 
formulations EM1-EM8 and AM1-AM8 are shown in 
table No.10 and table No.11 respectively. 
Table 10: Flatness of formulations EM1-EM8 
Formulation 
code 
Flatness (%) 
Mean±SD 
RSD % 
EM1 99.62±1.12 1.12 
EM2 99.26±1.44 1.45 
EM3 99.68±1.11 1.11 
EM4 99.55±1.65 1.65 
EM5 99.33±1.53 1.54 
EM6 99.50±1.05 1.05 
EM7 99.12±1.01 1.01 
EM8 99.63±1.45 1.45 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
                 Table 11: Flatness of formulations AM1-
AM8 
Formulation code 
Flatness(%) 
Mean±SD 
RSD % 
AM1 99.40±1.66 1.67 
AM2 99.59±1.15 1.15 
AM3 99.47±1.49 1.49 
AM4 99.38±1.71 1.72 
AM5 99.56±1.43 1.43 
AM6 99.37±1.19 1.19 
AM7 99.31±1.53 1.54 
AM8 99.65±1.44 1.45 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
Tensile strength 
Strength of the film and the risk of film cracking were 
indicated by its tensile strength. The Tensile 
strength of all the formulations was in the range of 0.442
±0.0132 to 0.538±0.0121 (EM1 to EM8 and AM1 to 
AM8). The prepared transdermal films were shown good 
tensile strength and there was no sign of cracking in 
prepared transdermal film. Tensile strength test results 
showed that the patch contains Methocel K15M in lower 
amount were more strengthens. There is increase in 
tensile strength with increase in Ammonio Methacrylate 
Copolymers or Methacrylic acid co-polymers in the 
polymer blend. The Tensile strength of the formulation 
EM1-EM8 and AM1-AM8 are shown in table No.12 and 
table No.13 respectively. 
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Table 12: Tensile strength of formulations EM1-EM8 
Formulation code Tensile strength (Kg/cm2) Mean±SD 
RSD % 
 
EM1 0.467±0.0115 2.46 
EM2 0.497±0.0129 2.59 
EM3 0.514±0.0133 2.58 
EM4 0.538±0.0121 2.24 
EM5 0.465±0.0127 2.73 
EM6 0.474±0.0115 2.42 
EM7 0.501±0.0119 2.37 
EM8 0.518±0.0131 2.52 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard deviation 
Table 13: Tensile strength of formulations AM1-AM8 
Formulation code Tensile strength (Kg/cm
2
) Mean±SD RSD % 
AM1 0.453±0.0121 2.67 
AM2 0.467±0.0116 2.48 
AM3 0.475±0.0122 2.56 
AM4 0.488±0.0111 2.27 
AM5 0.442±0.0132 2.98 
AM6 0.458±0.0114 2.48 
AM7 0.471±0.0125 2.65 
AM8 0.483±0.0050 2.67 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard deviation 
Percentage Elongation at break 
The % elongation at break gives an indication of the 
elasticity of the film. An inverse relation was observed 
between tensile strength and elongation at break. The % 
Elongation at 
break of all the formulations was in the range of 
71.22±1.44 % to 86.31±1.82 % (EM1 to EM8 and AM1 
to AM8). Elongation at break test (%) results showed 
that the patch contains Methocel K15M in higher amount 
were more strengthens. There is increase in % elongation 
at break with decrease in Ammonio Methacrylate 
Copolymers or Methacrylic acid co-polymers in the 
polymer blend. The % elongation at break of the 
formulation EM1-EM8 and AM1-AM8 are shown in 
table No.14 and table No.15 respectively. 
 
Table 14: % Elongation at break of formulations EM1-EM8 
Formulation code % Elongation at break Mean±SD RSD % 
EM1 76.180±1.51 1.98 
EM2 74.783±1.77 2.36 
EM3 73.163±1.59 2.17 
EM4 71.220±1.44 2.02 
EM5 79.403±1.79 2.25 
EM6 77.253±1.43 1.85 
EM7 74.380±1.62 2.17 
EM8 73.483±1.71 2.32 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard deviation 
 
Table 15: % Elongation at break of formulations AM1-AM8 
Formulation code % Elongation at break Mean±SD RSD % 
AM1 82.73±1.65 1.99 
AM2 80.51±1.52 1.88 
AM3 77.60±1.56 2.01 
AM4 75.60±1.62 2.14 
AM5 86.31±1.82 2.11 
AM6 83.58±1.49 1.78 
AM7 81.22±1.65 2.03 
AM8 78.04±1.77 2.27 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard deviation 
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Folding endurance  
The folding endurance was measured manually 
and it lies in the range of 121±2.89 to 154±2.29 (EM1 to 
EM8 and AM1 to AM8). It was found to be high in 
patches containing higher amount of the Eudragit and 
acrylcoat. T Folding endurance test results indicates that 
all the patches will withstand to rupture and would 
maintain their integrity with general skin folding, when 
used. There is increase in folding endurance with 
increase in Ammonio Methacrylate Copolymers or 
Methacrylic acid co-polymers in the polymer blend with 
Methocel K15M. The folding endurance of the 
formulation EM1-EM8 and AM1-AM8 are shown in 
table No.16 and table No.17 respectively.  
Table 16: Folding endurance of formulations EM1-
EM8 
Formulation 
code 
Folding endurance 
Mean±SD 
RSD 
% 
EM1 135.66±2.61 1.92 
EM2 144.33±2.93 2.03 
EM3 146.66±2.22 1.51 
EM4 154.00±2.29 1.48 
EM5 131.66±2.64 2.01 
EM6 138.00±2.25 1.63 
EM7 143.33±2.81 1.96 
EM8 145.33±2.77 1.91 
   
Table 17: Folding endurance of formulations AM1-
AM8 
 
Formulation 
code 
Folding endurance 
Mean±SD 
RSD 
% 
AM1 126.66±2.23 1.76 
AM2 132.66±2.27 1.71 
AM3 137.33±2.55 1.85 
AM4 142.66±2.21 1.54 
AM5 121.00±2.89 2.38 
AM6 127.33±2.69 2.11 
AM7 131.33±2.56 1.94 
AM8 139.00±2.81 2.02 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
Percentage moisture absorption 
The physicochemical studies like moisture loss and 
moisture uptake provide the information regarding the 
stability of the formulation. The % moisture uptake of 
the transdermal formulations was also low, which protect 
the film from microbial contamination as well as 
bulkiness of transdermal patch. The moisture 
absorption of all the formulations was in the range of 4.6
±0.109 % to 6.70±0.125 % (EM1 to EM8 and AM1 to 
AM8). The % Moisture absorption of the formulation 
EM1-EM8 and AM1-AM8 are shown in table No.18 and 
table No.19 respectively. 
 
 
 
 
Table 18: % Moisture absorption of formulations EM1-EM8 
Formulation 
code 
% Moisture absorption 
Mean±SD 
 
RSD 
% 
EM1 5.65±0.161 2.84 
EM2 5.17±0.083 1.61 
EM3 4.85±0.121 2.49 
EM4 4.60±0.109 2.36 
EM5 6.70±0.125 1.86 
EM6 5.95±0.115 1.93 
EM7 5.56±0.149 2.67 
EM8 5.15±0.133 2.58 
SD: Standard deviation; n=3; RSD %: % Relative Standard deviation 
Table 19: % Moisture absorption of formulations AM1-
AM8 
Formulation 
code 
%Moisture absorption 
Mean±SD 
RSD 
% 
AM1 5.84±0.146 2.50 
AM2 5.34±0.132 2.47 
AM3 5.05±0.091 1.80 
AM4 4.74±0.112 2.36 
AM5 6.13±0.157 2.56 
AM6 5.63±0.105 1.86 
AM7 5.24±0.151 2.88 
AM8 4.93±0.111 2.25 
SD: Standard deviation; n=3; RSD %: % Relative Standard deviation 
Percentage moisture loss 
 The % moisture loss of the prepared 
transdermal film was low, which maintains suppleness, 
thus preventing drying and brittleness.  The moisture 
content of all the formulations was in the range 
of 2.50±0.081 % to 3.80±0.088% (EM1 to EM8 and 
AM1 to AM8). Generally, the moisture uptake capacity 
of films increases with increasing hydrophilicity of the 
polymer or plasticizer. The formulations containing 
higher proportion of hydrophilic polymer Methocel 
K15M shows significant moisture absorption and 
moisture loss when compare to other patches having 
lower proportion of Methocel K15M. The moisture 
content of the Eudragit RLPO and Methocel K15M 
combination patches was higher compared to Eudragit 
RSPO and Methocel K15M combination patches due to 
relatively more hydrophobic nature of Eudragit RSPO 
than Eudragit RLPO. The % Moisture loss of the 
formulation EM1-EM8 and AM1-AM8 are shown in 
table No.20 and table No.21 respectively.  
Table 20: % Moisture Loss of formulations EM1-EM8 
Formulation 
code 
% Moisture loss 
Mean±SD 
RSD 
% 
EM1 2.95±0.058 1.96 
EM2 2.75±0.069 2.51 
EM3 2.62±0.052 1.98 
EM4 2.50±0.081 3.24 
EM5 3.80±0.088 2.31 
EM6 3.64±0.049 1.34 
EM7 3.35±0.064 1.91 
EM8 3.15±0.085 2.69 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
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Table 21: % Moisture Loss of formulations AM1-
AM8 
Formulation 
code 
% Moisture loss 
Mean±SD 
RSD 
% 
AM1 3.14±0.052 1.65 
AM2 2.95±0.045 1.52 
AM3 2.74±0.057 2.08 
AM4 2.58±0.086 3.33 
AM5 3.44±0.079 2.29 
AM6 3.24±0.058 1.79 
AM7 3.07±0.042 1.36 
AM8 2.94±0.083 2.82 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
Swelling Studies 
Percentage swelling varied between 11.15±0.31 to 
20.65±0.56 % (EM1 to EM8 and AM1 to AM8) for 
different polymeric patches. Hydrophilic polymers 
showed considerable swelling, as it increased the surface 
wettability and consequently water penetration within the 
matrix. The formulations containing higher proportion of 
hydrophilic polymer MK15M shows significant 
swellability when compare to other patches having lower 
proportion of MK15M.  
Table 22: % Swelling of formulations EM1-EM8 
Formulation code % Swelling Mean±SD RSD % 
EM1 14.68±0.41 2.79 
EM2 13.31±0.39 2.93 
EM3 12.61±0.32 2.53 
EM4 11.15±0.31 2.70 
EM5 20.65±0.56 2.71 
EM6 18.51±0.36 1.94 
EM7 17.55±0.46 2.62 
EM8 16.5±0.31 1.87 
   
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
The % swellability of the ERLPO and MK15M 
combination patches was higher compared to ERSPO 
and MK15M combination patches due to relatively more 
hydrophobic nature of ERSPO than ERLPO. The % 
Swelling of the formulation EM1-EM8 and AM1-AM8 
are shown in table No.22 and table No.23 respectively. 
 
Table 23:% Swelling of formulations AM1-AM8 
Formulation code 
% Swelling 
Mean±SD 
RSD % 
AM1 16.47±0.48 2.91 
AM2 15.42±0.31 2.01 
AM3 14.58±0.36 2.46 
AM4 13.44±0.38 2.82 
AM5 18.57±0.32 1.72 
AM6 16.52±0.35 2.11 
AM7 15.41±0.46 2.98 
AM8 14.36±0.41 2.85 
SD: Standard deviation; n=3; RSD %: Percentage Relative Standard 
deviation 
CONCLUSION 
From the above experimental results it can be reasonably 
concluded that The Monolithic Matrix type of 
transdermal films of Metoprolol tartrate developed in this 
study have great utility and are a viable option for 
effective and controlled management of hypertension. 
The monolithic matrix type transdermal patches were 
prepared by film casting technique on mercury substrate 
using different ratios of ERSPO: MK15M, ELSPO: 
MK15M, AS100: MK15M and AL100: MK15M 
(1:4,2:3,3:2,4:1)  and evaluated for physico-chemical 
properties for suitability and acceptability of the prepared 
patches. The thickness, weight, drug content, tensile 
strength, % elongation, folding endurance, flatness % 
absorption and % loss, swelling and pH were determined 
for the prepared patches. Physicochemical evaluation and 
appropriate quality control are essential to ensure safety 
and adequate performance of designed formulae.
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